T
Thomas F. Patterson
Researcher at University of Texas Health Science Center at San Antonio
Publications - 290
Citations - 39352
Thomas F. Patterson is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Aspergillosis & Fluconazole. The author has an hindex of 72, co-authored 289 publications receiving 34224 citations. Previous affiliations of Thomas F. Patterson include University of Texas at Austin & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben E. De Pauw,Thomas J. Walsh,J. Peter Donnelly,David A. Stevens,John E. Edwards,Thierry Calandra,Peter G. Pappas,Johan Maertens,Olivier Lortholary,Carol A. Kauffman,David W. Denning,Thomas F. Patterson,Georg Maschmeyer,Jacques Bille,William E. Dismukes,Raoul Herbrecht,William W. Hope,Christopher C. Kibbler,Bart Jan Kullberg,Kieren A. Marr,Patricia Muñoz,Frank C. Odds,John R. Perfect,Angela Restrepo,Markus Ruhnke,Brahm H. Segal,Jack D. Sobel,Tania C. Sorrell,Claudio Viscoli,John R. Wingard,Theoklis E. Zaoutis,John E. Bennett +31 more
TL;DR: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
Journal ArticleDOI
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Raoul Herbrecht,David W. Denning,David W. Denning,Thomas F. Patterson,John E. Bennett,Reginald Greene,Reginald Greene,J. W. Oestmann,Winfried V. Kern,Winfried V. Kern,Winfried V. Kern,Kieren A. Marr,Patricia Ribaud,Olivier Lortholary,Richard J. Sylvester,Robert H. Rubin,John R. Wingard,Paul Stark,Christine Durand,Denis Caillot,Eckhard Thiel,Pranatharthi H. Chandrasekar,Michael R. Hodges,Haran T. Schlamm,Peter F. Troke,Ben E. De Pauw +25 more
TL;DR: In patients with invasive aspergillosis,Initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B.
Journal ArticleDOI
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
Thomas J. Walsh,Elias Anaissie,David W. Denning,Raoul Herbrecht,Dimitrios P. Kontoyiannis,Kieren A. Marr,Vicki A. Morrison,Vicki A. Morrison,Brahm H. Segal,William J. Steinbach,David A. Stevens,David A. Stevens,Jo Anne H. Van Burik,John R. Wingard,Thomas F. Patterson +14 more
TL;DR: This research presents a novel, scalable, scalable and scalable approach that allows for real-time evaluation of the impact of Epstein-Barr virus on the development and management of childhood cancer in rats.
Journal ArticleDOI
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
Sibel Ascioglu,John H. Rex,B.E. de Pauw,John E. Bennett,J. Bille,F. Crokaert,David W. Denning,J.P. Donnelly,J. E. Edwards,Z. Erjavec,D. Fiere,O. Lortholary,Johan Maertens,Jacques F. Meis,Thomas F. Patterson,J. Ritter,D. Selleslag,Palak Shah,David A. Stevens,Thomas J. Walsh +19 more
TL;DR: A set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed and three levels of probability are proposed: "proven," "probable," and "possible."
Journal ArticleDOI
Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America
Thomas F. Patterson,George Richard Thompson,David W. Denning,Jay A. Fishman,Susan Hadley,Raoul Herbrecht,Dimitrios P. Kontoyiannis,Kieren A. Marr,Vicki A. Morrison,M. Hong Nguyen,Brahm H. Segal,William J. Steinbach,David A. Stevens,Thomas J. Walsh,John R. Wingard,Jo Anne H. Young,John E. Bennett +16 more
TL;DR: IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.